Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Entospletinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK known ✓ | P43405 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | ROS1 | P08922 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | CSNK2B | P67870 | 1/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 1/20 | 1.00 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Entospletinib SCHEMBL29355138 | 1.00 | SYK (1.00) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2481530 | 0.97 | SYK (1.00) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| Entospletinib SCHEMBL23777555 | 0.94 | SYK (0.89) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| Entospletinib SCHEMBL19283440 | 0.94 | SYK (0.89) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2893760 | 0.93 | SYK (0.87) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2480971 | 0.93 | SYK (0.87) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL3422119 | 0.92 | SYK (0.86) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2478771 | 0.92 | SYK (0.84) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2482901 | 0.91 | SYK (0.87) | SYKJAK2NTRK1ROS1CSNK2A2 | |
| SCHEMBL2479102 | 0.91 | SYK (0.84) | SYKJAK2NTRK1ROS1CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 787 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191098-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016040858-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| US-20260144794-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCERS | Pattern Computer, Inc. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3870566-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026089992-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| EP-2373169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | disclosed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | disclosed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | disclosed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144794-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCERS | FLT3, BRAF, ERBB2 | SYK 497/4885JAK2 13/4885NTRK1 733/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | SYK 4313/4885JAK2 4082/4885NTRK1 260/4885 |
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | SYK 1/4885JAK2 16/4885NTRK1 559/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | SYK 2882/4885JAK2 1830/4885NTRK1 3746/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | SYK 3687/4885JAK2 2055/4885NTRK1 4501/4885 |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | SYK 1/4885JAK2 16/4885NTRK1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.